STX8

Summary

STX8 (syntaxin 8, HGNC:11443) is a protein-coding gene on chromosome 17p13.1, encoding Syntaxin-8 (Q9UNK0). Vesicle trafficking protein that functions in the early secretory pathway, possibly by mediating retrograde transport from cis-Golgi membranes to the ER.

The gene is a member of the syntaxin family. The encoded protein is involved in protein trafficking from early to late endosomes via vesicle fusion and exocytosis. A related pseudogene has been identified on chromosome 12. Alternative splicing results in multiple transcript variants.

Source: NCBI Gene 9482 — RefSeq curated summary.

At a glance

• GWAS associations: 6
• Clinical variants (ClinVar): 50 total
• MANE Select transcript: NM_004853

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:11443
Approved symbol	STX8
Name	syntaxin 8
Location	17p13.1
Locus type	gene with protein product
Status	Approved
Aliases	CARB
Ensembl gene	ENSG00000170310
Ensembl biotype	protein_coding
OMIM	604203
Entrez	9482

Gene structure

Transcript identifiers

Ensembl transcripts: 13 — 5 protein_coding_CDS_not_defined, 4 protein_coding, 2 retained_intron, 2 nonsense_mediated_decay

ENST00000306357, ENST00000570583, ENST00000570987, ENST00000573016, ENST00000573077, ENST00000573373, ENST00000573881, ENST00000574382, ENST00000574431, ENST00000574775, ENST00000575294, ENST00000575858, ENST00000951848

RefSeq mRNA: 1 — MANE Select: NM_004853 NM_004853

CCDS: CCDS32565

Canonical transcript exons

ENST00000306357 — 8 exons

Exon	Start	End
ENSE00002644691	9575792	9575820
ENSE00003541249	9545172	9545282
ENSE00003561682	9250471	9250645
ENSE00003586284	9378552	9378653
ENSE00003609821	9491829	9491921
ENSE00003639795	9505038	9505162
ENSE00003703352	9568371	9568470
ENSE00003710971	9557434	9557528

Expression profiles

Bgee: expression breadth ubiquitous, 292 present calls, max score 97.62.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 17.4035 / max 398.8763, expressed in 1798 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
164496	17.3259	1798
164494	0.0775	28

Top tissues by expression

295 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
sperm	CL:0000019	97.62	gold quality
left testis	UBERON:0004533	96.86	gold quality
right testis	UBERON:0004534	96.81	gold quality
male germ cell	CL:0000015	96.64	gold quality
calcaneal tendon	UBERON:0003701	95.98	gold quality
mucosa of stomach	UBERON:0001199	95.79	gold quality
oocyte	CL:0000023	95.77	gold quality
testis	UBERON:0000473	95.77	gold quality
lower esophagus muscularis layer	UBERON:0035833	95.65	gold quality
lower esophagus	UBERON:0013473	95.63	gold quality
tendon	UBERON:0000043	95.51	gold quality
islet of Langerhans	UBERON:0000006	95.32	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	95.31	gold quality
popliteal artery	UBERON:0002250	95.29	gold quality
tibial artery	UBERON:0007610	95.29	gold quality
muscle layer of sigmoid colon	UBERON:0035805	95.29	gold quality
aorta	UBERON:0000947	95.07	gold quality
hindlimb stylopod muscle	UBERON:0004252	95.02	gold quality
ascending aorta	UBERON:0001496	94.91	gold quality
thoracic aorta	UBERON:0001515	94.89	gold quality
left coronary artery	UBERON:0001626	94.84	gold quality
descending thoracic aorta	UBERON:0002345	94.80	gold quality
monocyte	CL:0000576	94.68	gold quality
ganglionic eminence	UBERON:0004023	94.67	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	94.63	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	94.62	gold quality
coronary artery	UBERON:0001621	94.45	gold quality
leukocyte	CL:0000738	94.43	gold quality
mononuclear cell	CL:0000842	94.42	gold quality
granulocyte	CL:0000094	94.30	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

12 targeting STX8, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4723-5P	99.97	68.70	2034
HSA-MIR-7150	99.62	66.80	1322
HSA-MIR-6751-5P	99.56	64.99	1145
HSA-MIR-3147	99.52	66.34	388
HSA-MIR-1275	99.47	67.90	2749
HSA-MIR-6803-5P	99.19	63.90	1026
HSA-MIR-7109-5P	99.18	66.13	1057
HSA-MIR-625-5P	99.02	68.64	2031
HSA-MIR-4736	97.96	65.89	1287
HSA-MIR-4665-5P	97.91	67.69	1536
HSA-MIR-215-3P	97.02	68.01	1209
HSA-MIR-597-5P	96.82	67.57	732

Literature-anchored findings (GeneRIF, showing 12)

• There are increases in CARB localized to intraneuronal neurofibrillary tangles and granulovacuolar degeneration in susceptible hippocampal and cortical neurons in Alzheimer’s disease. (PMID:14991845)
• syntaxin 8 contributes to the regulation of CFTR trafficking and chloride channel activity by the SNARE machinery (PMID:15039462)
• Has two functionally distinct di-leucine-based motifs that act independently in its endocytic and exocytic processes. (PMID:17965969)
• Results report that syntaxin 7, syntaxin 8, vti1b and VAMP8 physically and functionally interact with CFTR. (PMID:18570918)
• Palmitoylation does not affect the rate of protein turnover of syntaxins 7 and 8 nor does it influence the steady-state localization of syntaxin 8 in late endosomes. (PMID:18980942)
• These results suggest that STX8 mediates the recycling of CLDN16 and constitutes an important component of the CLDN16 trafficking machinery in the kidney. (PMID:24659781)
• Syntaxin-8 regulates the endocytosis of TASK-1. (PMID:24743596)
• Syntaxin 8 has a role in regulating platelet dense granule secretion, aggregation, and thrombus stability (PMID:25404741)
• Increased STX8 expression in visceral adipose tissue appears to be associated with the presence of type 2 diabetes in obese patients through a mechanism that may involve GLUT4. (PMID:25523146)
• Stx8 is required for proper and timely sorting and trafficking of cytotoxic molecules to functional lytic granules through the endosomal pathway in human cytotoxic t-lymphocytes. (PMID:27094127)
• STX8 silencing restores the function ofDeltaF508-CFTR. (PMID:30485852)
• Smuggle tau through a secret(ory) pathway. (PMID:34319403)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	stx8	ENSDARG00000103173
mus_musculus	Stx8	ENSMUSG00000020903
rattus_norvegicus	Stx8	ENSRNOG00000003849
drosophila_melanogaster	Syx6	FBGN0037084
caenorhabditis_elegans		WBGENE00015789

Paralogs (2): STX10 (ENSG00000104915), STX6 (ENSG00000135823)

Protein

Protein identifiers

Syntaxin-8 — Q9UNK0 (reviewed: Q9UNK0)

All UniProt accessions (5): Q9UNK0, I3L305, I3L3D0, K7EQB1, K7ER37

UniProt curated annotations — full annotation on UniProt →

Function. Vesicle trafficking protein that functions in the early secretory pathway, possibly by mediating retrograde transport from cis-Golgi membranes to the ER.

Subunit / interactions. Forms a SNARE complex with STX7, VTI1B and VAMP8 which functions in the homotypic fusion of late endosomes. Part of the SNARE core complex containing STX7, VAMP8 and VTI1B. Interacts with VAMP8. Interacts with HECTD3. Interacts with TPC1.

Subcellular location. Membrane.

Tissue specificity. Highly expressed in heart. Also found in brain, kidney, liver, lung, placenta, skeletal muscle, spleen and pancreas.

Post-translational modifications. Ubiquitinated by HECTD3.

Similarity. Belongs to the syntaxin family.

RefSeq proteins (1): NP_004844* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000727	T_SNARE_dom	Domain
IPR041875	Syntaxin-8_SNARE	Domain
IPR045242	Syntaxin	Family

Pfam: PF05739

UniProt features (8 total): topological domain 2, chain 1, transmembrane region 1, domain 1, coiled-coil region 1, modified residue 1, sequence conflict 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9UNK0-F1	76.58	0.19

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (1): 160

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 167 (showing top): BUYTAERT_PHOTODYNAMIC_THERAPY_STRESS_DN, GOBP_INTRACELLULAR_PROTEIN_TRANSPORT, GOBP_RESPONSE_TO_PEPTIDE, GOBP_VESICLE_ORGANIZATION, GOBP_MEMBRANE_FUSION, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_DN, GRAESSMANN_RESPONSE_TO_MC_AND_DOXORUBICIN_DN, GOBP_VESICLE_MEDIATED_TRANSPORT, GOBP_PROTEIN_LOCALIZATION_TO_CELL_PERIPHERY, GOBP_MEMBRANE_DOCKING, GOCC_TRANS_GOLGI_NETWORK, GOBP_DEFENSE_RESPONSE_TO_OTHER_ORGANISM, GOBP_ORGANELLE_MEMBRANE_FUSION, GOBP_REGULATION_OF_CELLULAR_LOCALIZATION, SCHLOSSER_SERUM_RESPONSE_DN

GO Biological Process (6): intracellular protein transport (GO:0006886), vesicle fusion (GO:0006906), early endosome to late endosome transport (GO:0045022), obsolete vesicle docking (GO:0048278), cellular response to type II interferon (GO:0071346), regulation of protein localization to plasma membrane (GO:1903076)

GO Molecular Function (6): SNARE binding (GO:0000149), SNAP receptor activity (GO:0005484), chloride channel inhibitor activity (GO:0019869), syntaxin binding (GO:0019905), ubiquitin protein ligase binding (GO:0031625), protein binding (GO:0005515)

GO Cellular Component (14): endosome (GO:0005768), early endosome (GO:0005769), late endosome (GO:0005770), endoplasmic reticulum (GO:0005783), trans-Golgi network (GO:0005802), plasma membrane (GO:0005886), endomembrane system (GO:0012505), SNARE complex (GO:0031201), vesicle (GO:0031982), phagocytic vesicle (GO:0045335), perinuclear region of cytoplasm (GO:0048471), recycling endosome (GO:0055037), Golgi apparatus (GO:0005794), membrane (GO:0016020)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cytoplasm	5
endomembrane system	3
endosome	3
cellular anatomical structure	3
intracellular membrane-bounded organelle	2
intracellular protein localization	1
protein transport	1
intracellular transport	1
vesicle organization	1
vesicle-mediated transport	1
organelle membrane fusion	1
vesicle-mediated transport between endosomal compartments	1
response to type II interferon	1
cellular response to cytokine stimulus	1
protein localization to plasma membrane	1
regulation of protein localization to cell periphery	1
regulation of protein localization to membrane	1
protein binding	1
protein-macromolecule adaptor activity	1
membrane fusion	1
fusogenic activity	1
chloride channel activity	1
ion channel inhibitor activity	1
chloride channel regulator activity	1
SNARE binding	1
ubiquitin-like protein ligase binding	1
binding	1
cytoplasmic vesicle	1
Golgi apparatus subcompartment	1
membrane	1
cell periphery	1
vacuole	1
plasma membrane	1
membrane protein complex	1
membrane-bounded organelle	1
endocytic vesicle	1

Protein interactions and networks

STRING

1370 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
STX8	STX7	O15400	999
STX8	VTI1B	Q9UEU0	996
STX8	VAMP8	Q9BV40	994
STX8	VAMP7	P51809	978
STX8	STX12	Q86Y82	936
STX8	STX3	Q13277	886
STX8	STX4	Q12846	863
STX8	SNAP29	O95721	860
STX8	VPS33A	Q96AX1	830
STX8	STX1A	Q16623	816
STX8	STX16	O14662	813
STX8	TXLNB	Q8N3L3	763
STX8	TXLNG	Q9NUQ3	760
STX8	VPS33B	Q9H267	741
STX8	NAPA	P54920	737

IntAct

388 interactions, top by confidence:

A	B	Type	Score
STX8	VTI1B	psi-mi:“MI:0915”(physical association)	0.920
STX8	STX4	psi-mi:“MI:0915”(physical association)	0.780
STX4	STX8	psi-mi:“MI:0915”(physical association)	0.780
AP1S2	AP1G1	psi-mi:“MI:0914”(association)	0.670
STX5	STX8	psi-mi:“MI:0915”(physical association)	0.670
TRDN	TMEM223	psi-mi:“MI:0914”(association)	0.640
GPR156	PLD2	psi-mi:“MI:0914”(association)	0.640
ASPH	STXBP3	psi-mi:“MI:0914”(association)	0.640
STAMBPL1	PIK3C2A	psi-mi:“MI:0914”(association)	0.640
JSRP1	STX8	psi-mi:“MI:0915”(physical association)	0.630
TMED8	STX8	psi-mi:“MI:0915”(physical association)	0.600
STX8		psi-mi:“MI:0915”(physical association)	0.560
STX8	CD79A	psi-mi:“MI:0915”(physical association)	0.560
STX8	TMPPE	psi-mi:“MI:0915”(physical association)	0.560
STX8	MTERF3	psi-mi:“MI:0915”(physical association)	0.560
STX8	MGST2	psi-mi:“MI:0915”(physical association)	0.560
STX8	GPR42	psi-mi:“MI:0915”(physical association)	0.560
STX8	GPR151	psi-mi:“MI:0915”(physical association)	0.560
STX8	SCN3B	psi-mi:“MI:0915”(physical association)	0.560
STX8	NDUFAF1	psi-mi:“MI:0915”(physical association)	0.560
STX8	AMIGO1	psi-mi:“MI:0915”(physical association)	0.560
STX8	FNDC9	psi-mi:“MI:0915”(physical association)	0.560

BioGRID (363): STX8 (Two-hybrid), STX8 (Affinity Capture-Western), STX8 (Affinity Capture-Western), STX8 (Affinity Capture-Western), STX8 (Affinity Capture-Western), STX8 (Affinity Capture-MS), STX8 (Affinity Capture-MS), STX8 (Affinity Capture-MS), STX8 (Affinity Capture-MS), STX8 (Affinity Capture-MS), STX8 (Affinity Capture-MS), STX8 (Affinity Capture-MS), STX8 (Affinity Capture-MS), STX8 (Affinity Capture-MS), STX8 (Affinity Capture-MS)

ESM2 similar proteins: G3V7P1, O08522, O14662, O15400, O22151, O43752, O49377, O60499, O64791, O70257, O70439, O70480, O75379, O88384, O88630, O88983, O95249, P58200, Q08851, Q08DB5, Q13190, Q2KIU0, Q2TBU3, Q32L97, Q3T075, Q3ZBT5, Q5R602, Q5R6Q2, Q5RBL6, Q5RBW6, Q5RF94, Q5SRX1, Q5ZL19, Q62931, Q63635, Q86Y82, Q8BVI5, Q8K1E0, Q944A9, Q946Y7

Diamond homologs: O88983, P83528, Q3T075, Q63635, Q9JKK1, Q9UNK0, Q9Z2Q7, O43752, O60499, Q54IX6, Q5R6Q2, Q5ZL19, Q946Y7, Q9HGN3, O14222, Q553P5, Q9SA23

SIGNOR signaling

1 interactions.

A	Effect	B	Mechanism
HECTD3	“down-regulates quantity by destabilization”	STX8	polyubiquitination

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 131 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
trans-Golgi Network Vesicle Budding	8	23.9×	9e-08
Golgi Associated Vesicle Biogenesis	10	23.6×	1e-09
Intra-Golgi traffic	6	18.3×	5e-05
Retrograde transport at the Trans-Golgi-Network	6	15.5×	9e-05
Intra-Golgi and retrograde Golgi-to-ER traffic	8	9.9×	7e-05
COPII-mediated vesicle transport	5	9.6×	6e-03
Membrane Trafficking	18	7.8×	1e-09
Vesicle-mediated transport	18	7.4×	2e-09

GO biological processes:

GO term	Partners	Fold	FDR
obsolete vesicle docking	9	61.5×	3e-12
vesicle fusion	8	43.0×	2e-09
membrane fusion	5	27.9×	1e-04
retrograde vesicle-mediated transport, Golgi to endoplasmic reticulum	5	15.1×	1e-03
intracellular protein transport	19	11.0×	3e-12
exocytosis	7	9.5×	9e-04
cellular response to type II interferon	5	9.3×	9e-03
retrograde transport, endosome to Golgi	5	9.2×	9e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

50 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	37
Likely benign	3
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

3916 predictions. Top by Δscore:

Variant	Effect	Δscore
17:9378652:CT:C	acceptor_gain	1.0000
17:9378654:C:CC	acceptor_gain	1.0000
17:9491917:CTGTT:C	acceptor_gain	1.0000
17:9491918:TGTT:T	acceptor_gain	1.0000
17:9491919:GTT:G	acceptor_gain	1.0000
17:9491920:TT:T	acceptor_gain	1.0000
17:9491921:TCTG:T	acceptor_loss	1.0000
17:9491922:C:CC	acceptor_gain	1.0000
17:9491922:C:CG	acceptor_loss	1.0000
17:9491923:T:C	acceptor_loss	1.0000
17:9557424:A:AC	donor_gain	1.0000
17:9557425:C:CC	donor_gain	1.0000
17:9557433:CAT:C	donor_gain	1.0000
17:9557459:G:C	donor_gain	1.0000
17:9557467:T:TA	donor_gain	1.0000
17:9378550:A:AC	donor_gain	0.9900
17:9378551:C:CC	donor_gain	0.9900
17:9378551:CCA:C	donor_gain	0.9900
17:9378649:TATCT:T	acceptor_gain	0.9900
17:9450992:A:T	acceptor_gain	0.9900
17:9491823:TCTTA:T	donor_loss	0.9900
17:9491824:CTTAC:C	donor_loss	0.9900
17:9491825:TTAC:T	donor_loss	0.9900
17:9491826:TA:T	donor_loss	0.9900
17:9491827:A:AC	donor_gain	0.9900
17:9491828:C:CC	donor_gain	0.9900
17:9491828:C:CT	donor_loss	0.9900
17:9494779:ACGAT:A	donor_gain	0.9900
17:9494780:CGATC:C	donor_gain	0.9900
17:9494853:T:TA	donor_gain	0.9900

AlphaMissense

1550 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
17:9491879:C:G	R164P	0.997
17:9491906:A:G	L155P	0.995
17:9545258:T:A	R79S	0.995
17:9545258:T:G	R79S	0.995
17:9545259:C:G	R79T	0.995
17:9378638:A:G	L186P	0.994
17:9491897:A:G	L158P	0.993
17:9491897:A:T	L158H	0.993
17:9250621:A:C	L223R	0.992
17:9491885:A:T	I162K	0.992
17:9491865:C:G	G169R	0.991
17:9491865:C:T	G169R	0.991
17:9250621:A:G	L223P	0.990
17:9491906:A:T	L155H	0.990
17:9545262:C:G	R78P	0.990
17:9250612:G:T	A226D	0.989
17:9378605:A:G	L197P	0.989
17:9575793:A:G	W6R	0.989
17:9575793:A:T	W6R	0.989
17:9491864:C:T	G169E	0.988
17:9491918:T:G	Q151P	0.988
17:9545238:A:G	L86P	0.988
17:9491895:A:G	S159P	0.987
17:9491876:T:G	Q165P	0.986
17:9491901:C:G	A157P	0.986
17:9557494:A:G	L51P	0.986
17:9250621:A:T	L223Q	0.985
17:9491865:C:A	G169W	0.983
17:9250618:A:C	L224R	0.982
17:9491834:T:G	Q179P	0.982

dbSNP variants (sampled 300 via entrez): RS1000000024 (17:9264852 G>A), RS1000003369 (17:9385261 G>A,C), RS1000013017 (17:9399100 C>T), RS1000014621 (17:9551749 T>A), RS1000028286 (17:9500019 A>G), RS1000031205 (17:9421678 C>A,T), RS1000033883 (17:9565511 G>A), RS1000042235 (17:9474920 T>C), RS1000075634 (17:9455405 C>G,T), RS1000078945 (17:9559714 A>G,T), RS1000089356 (17:9520074 C>A), RS1000109701 (17:9302750 A>G), RS1000115725 (17:9252938 G>A), RS1000121388 (17:9521153 G>C), RS1000123680 (17:9574121 A>T)

Disease associations

OMIM: gene MIM:604203 | disease phenotypes:

GenCC curated gene-disease

Mondo (1): prostate cancer (MONDO:0008315)

Orphanet (1): Familial prostate cancer (Orphanet:1331)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

6 associations (top):

Study	Trait	p-value
GCST004641_6	Borderline personality disorder	3.000000e-06
GCST004763_3	HDL cholesterol change in response to fenofibrate in statin-treated type 2 diabetes	1.000000e-06
GCST005051_29	Obstructive sleep apnea trait (apnea hypopnea index)	4.000000e-07
GCST006585_2988	Blood protein levels	1.000000e-07
GCST010396_114	Gut microbiota (bacterial taxa, hurdle binary method)	7.000000e-07
GCST010703_159	Brain morphology (MOSTest)	3.000000e-09

EFO canonical traits (4, from GWAS)

EFO ID	Trait name
EFO:0007805	HDL cholesterol change measurement
EFO:0007817	sleep apnea measurement
EFO:0007874	gut microbiome measurement
EFO:0004346	neuroimaging measurement

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D011471	Prostatic Neoplasms	C04.588.945.440.770; C12.100.500.260.750; C12.100.500.565.625; C12.200.294.260.750; C12.200.294.565.625; C12.200.758.409.750; C12.900.619.750

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

34 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Benzo(a)pyrene	affects methylation, decreases expression	7
Aflatoxin B1	affects expression, decreases expression, increases methylation	5
bisphenol A	affects cotreatment, decreases methylation, increases expression	2
bisphenol S	increases expression, affects cotreatment	2
Cisplatin	affects cotreatment, decreases expression	2
Valproic Acid	affects expression, decreases methylation	2
Particulate Matter	decreases expression, increases abundance, increases expression, affects cotreatment	2
aristolochic acid I	decreases expression	1
FR900359	decreases phosphorylation	1
dicrotophos	decreases expression	1
methyleugenol	decreases expression	1
cobaltous chloride	decreases expression	1
aflatoxin B2	affects methylation	1
isobutyl alcohol	affects cotreatment, decreases expression, increases abundance	1
corosolic acid	decreases expression	1
jinfukang	affects cotreatment, decreases expression	1
(+)-JQ1 compound	decreases expression	1
Sunitinib	increases expression	1
Fulvestrant	decreases methylation, affects cotreatment	1
Caffeine	decreases phosphorylation	1
Dexamethasone	affects cotreatment, increases expression	1
Estradiol	decreases expression	1
Formaldehyde	decreases expression	1
Gasoline	increases abundance, affects cotreatment, decreases expression	1
Indomethacin	increases expression, affects cotreatment	1
Ivermectin	decreases expression	1
Mustard Gas	decreases expression	1
Polycyclic Aromatic Hydrocarbons	affects cotreatment, decreases expression, increases abundance	1
Tobacco Smoke Pollution	increases methylation	1
1-Methyl-3-isobutylxanthine	affects cotreatment, increases expression	1

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00029224	PHASE4	COMPLETED	Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions
NCT00035997	PHASE4	COMPLETED	Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis
NCT00063609	PHASE4	COMPLETED	The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy
NCT00103623	PHASE4	SUSPENDED	The Plenaxis® Experience Study
NCT00106392	PHASE4	COMPLETED	A Safety and Efficacy Study of Prograf in the Prevention of Erectile Dysfunction After Radical Prostatectomy
NCT00185029	PHASE4	UNKNOWN	MR-Lymphography and Lymph Node Staging in Prostate Cancer
NCT00199485	PHASE4	COMPLETED	Angelica Sinensis for the Treatment of Hot Flashes in Men Undergoing LHRH Therapy for Prostate Cancer
NCT00219219	PHASE4	COMPLETED	Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases
NCT00219271	PHASE4	COMPLETED	Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer
NCT00237146	PHASE4	COMPLETED	Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy
NCT00242554	PHASE4	COMPLETED	Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases
NCT00280098	PHASE4	COMPLETED	Docetaxel in the Treatment of Hormone Refractory Prostate Cancer
NCT00293696	PHASE4	COMPLETED	Casodex/Zoladex Biomarkers in Localised Prostate Cancer
NCT00334139	PHASE4	COMPLETED	Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer
NCT00375765	PHASE4	COMPLETED	Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer
NCT00391690	PHASE4	COMPLETED	Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer
NCT00422708	PHASE4	COMPLETED	Local Anesthesia for Prostate Biopsy
NCT00526331	PHASE4	COMPLETED	Evaluation of Arterial Pressure Based Cardiac Output for Goal-Directed Perioperative Therapy
NCT00590213	PHASE4	COMPLETED	Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX
NCT00629330	PHASE4	TERMINATED	Dissemination of Prostate Cancer Screening to PCP’s in African American Communities
NCT00771966	PHASE4	COMPLETED	Radical Prostatectomy and Perioperative Fluid Therapy
NCT00805701	PHASE4	COMPLETED	Study Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving Urinary Symptoms In Men With Prostate Cancer Who Are Undergoing Seed Implantation
NCT00859027	PHASE4	COMPLETED	Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer
NCT00906269	PHASE4	UNKNOWN	Can Hyperbaric Oxygen Improve Erectile Function Following Surgery for Prostate Cancer
NCT00953277	PHASE4	COMPLETED	Study of Nerve Reconstruction Using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer
NCT00982800	PHASE4	COMPLETED	Does Postoperative Gabapentin Reduce Pain, Opioid Consumption and Anxiety and Have a Positive Effect on Health Related Quality of Life After Radical Prostatectomy?
NCT01083199	PHASE4	COMPLETED	Global Performance Evaluation of the AMS CONTINUUM™ Device
NCT01136226	PHASE4	COMPLETED	Evaluate Recovery of Testosterone for Patients Using Eligard
NCT01161563	PHASE4	COMPLETED	Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration
NCT01230905	PHASE4	COMPLETED	Study to Monitor the Effects of Androgen Suppression Treatment on the Heart
NCT01296672	PHASE4	COMPLETED	3 Month Finasteride Challenge Test Can Significantly Improve the Performance of Screening for Prostate Cancer
NCT01365143	PHASE4	TERMINATED	Prospective Randomized Trial Comparing Robotic Versus Open Radical Prostatectomy
NCT01379742	PHASE4	UNKNOWN	Comparison of Between ThinSeed™ and OncoSeed™ for Permanent Prostate Brachytherapy
NCT01486563	PHASE4	COMPLETED	Hydroxyethyl Starch and Renal Function After Radical Prostatectomy
NCT01511874	PHASE4	COMPLETED	Efficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer
NCT01512472	PHASE4	TERMINATED	Firmagon (Degarelix) Intermittent Therapy
NCT01547416	PHASE4	COMPLETED	The Effect of Combined General/Epidural Anesthesia Versus General Anesthesia on Diaphragmatic Function
NCT01571544	PHASE4	COMPLETED	The Use of Thermal Suits as Preventing Hypothermia During Surgery
NCT01581749	PHASE4	UNKNOWN	Evaluation of Truebeam for Low-Intermediate Risk Prostate Cancer
NCT01649635	PHASE4	COMPLETED	Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer